Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia

Stock Information for Cardiff Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cardiff Oncology Inc.

Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
Cardiff Oncology to Participate in September 2026 Conferences
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Cardiff Oncology Announces $10 Million Registered Direct Offering
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.